Young-Jack Lee – CEO, LSK Global PS, South Korea
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Address: 97 Toegye-Ro, Coryo Daeyungak Tower 16th Fl., Jung-Gu, Seoul 100-706 Republic of Korea
Tel: +82 2 546 1008
Web: http://www.lskglobal.com/
LSK Global PS is a Republic of Korean full service CRO in Seoul, Republic of Korea. LSK Global PS has been in business since March 2000. Although small yet, LSK is growing as fast as the number of multinational trials in Republic of Korea recently (see the chart below). Just five of us started LSK Global PS eight years ago.
Now we have grown to sixty. To meet the increasing domestic and global demand for our services, we have moved to a bigger location recently
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth…
South Korea has a short history of participating in global clinical trials, but now the country is seeing exponential growth in this area. What has changed in recent years leading…
Julien Samson, vice president and general manager of GSK Korea explains how GSK’s new global strategy is being delivered within the Korean affiliate. Mr Samson explains the focus areas for…
As the 3rd largest pharma region in Asia, Korea’s booming pharma industry owes much to its mass of family-run conglomerates known as Chaebol. It comes as no surprise to find tech…
Shingyu Bae, CEO of MDimune, explains how the company’s new exosome drug delivery system increases efficacy and reduces toxicity compared with other oncology products. He also discusses the potential and…
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
See our Cookie Privacy Policy Here
